CNS Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 3, 2024, reports a material corporate action by CNS Pharmaceuticals, Inc. (CNSP). The filing details the execution of a reverse stock split approved by stockholders at the April 30, 2024, annual meeting. The split became effective at 4:01 p.m. Eastern Time on June 4, 2024.
Key Financial Metrics and Capital Structure
The filing does not report current revenue, operating cash flow, or liquidity positions. It focuses on the capital structure adjustment resulting from the reverse stock split:
- Split Ratio: 1-for-50 (1:50).
- Outstanding Shares: Reduced from approximately 16.25 million to approximately 325,000 shares.
- Authorized Shares: Remained at 300 million shares.
- Par Value: Remained at $0.001 per share.
- Trading Symbol: Remains "CNSP" on The Nasdaq Capital Market.
- CUSIP: Updated to 18978H300.
Historical Loss Data (Restated for Post-Split Basis):
| Period | Net Loss | Post-Split Loss Per Share (Basic) |
|---|---|---|
| 12 Months Ended Dec 31, 2023 | $(18,851,226) | $(250.19) |
| 12 Months Ended Dec 31, 2022 | $(15,274,134) | $(560.83) |
| 3 Months Ended Mar 31, 2024 | $(3,544,748) | $(20.34) |
| 3 Months Ended Mar 31, 2023 | $(4,931,947) | $(129.35) |
Material Changes
The primary material change is the reduction in the number of outstanding shares by a factor of 50. Consequently, the per-share exercise price and number of shares issuable for all outstanding stock options, restricted stock units, and warrants have been proportionately adjusted. No fractional shares were issued; fractional entitlements were rounded up to the nearest whole number.
Outlook and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary of the amendment is qualified by the full text of the attached Certificate of Amendment. The company expects trading on a split-adjusted basis to commence on June 5, 2024.
Investor Verification Checklist
- Verify the new CUSIP number (18978H300) for trading and settlement purposes.
- Confirm the adjusted exercise prices and share counts for any held options, warrants, or RSUs.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for specific terms regarding the rounding of fractional shares.
- Monitor the stock price and liquidity post-split, as the share count has been significantly reduced to approximately 325,000 shares.